{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:33:52Z","timestamp":1793720032042,"version":"4.6.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>General population normative values for the widely used health-related quality of life (HRQoL) measure EORTC QLQ-C30 support the interpretation of trial results and HRQoL of patients in clinical practice. Here, we provide sex-, age- and health condition-specific normative values for the EORTC QLQ-C30 in the French general population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>French general population data was collected in an international EORTC project. Online panels with quota samples were used to recruit sex and age groups. Number and type of comorbidities were assessed. Descriptive statistics were used to calculate general population values for each QLQ-C30 scale, separately for sex, age, and presence of one- and more chronic health conditions. A multivariate linear regression model has been developed to allow estimating the effect of sex, age, and the presence for one- and more chronic health conditions on EORTC QLQ-C30 scores. Data was weighted according to United Nation statistics adjusting for the proportion of sex and age groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 1001 French respondents were included in our analyses. The weighted mean age was 47.9 years, 514 (51.3%) participants were women, and 497 (52.2%) participants reported at least one health condition. Men reported statistically significant better scores for Emotional Functioning (+9.6 points, <jats:italic>p<\/jats:italic>\u2009=\u20090.006) and Fatigue (\u22127.8 point; <jats:italic>p<\/jats:italic>\u2009=\u20090.04); women reported better profiles for Role Functioning (+8.7 points; <jats:italic>p<\/jats:italic>\u2009=\u20090.008) and Financial Difficulty (\u22127.8 points, <jats:italic>p<\/jats:italic>\u2009=\u20090.011). According to the regression model, the sex effect was statistically significant in eight scales; the effect of increasing age had a statistically significant effect on seven of the 15 EORTC QLQ-C30 scales. The sex- and age effect varied in its direction across the various scales. The presence of health conditions showed a strong negative effect on all scales.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is the first publication of detailed French normative values for the EORTC QLQ-C30. It aims to support the interpretation of HRQoL profiles in French cancer populations. The strong impact of health conditions on QLQ-C30 scores highlights the importance of considering the impact of comorbidities in cancer patients when interpreting HRQoL data.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00719-7","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T12:02:17Z","timestamp":1714651337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["General population normative values for the EORTC QLQ-C30 by age, sex, and health condition for the French general population"],"prefix":"10.1186","volume":"8","author":[{"given":"Micha J.","family":"Pilz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny L.C.","family":"Loth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.M.","family":"Thurner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Gamper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Anota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Liegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EORTC Quality of Life Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"719_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, Hunn A, Bottomley A, Regnault A, Chan AW, Ells C, O\u2019Connor D, Revicki D, Patrick D, Altman D, Basch E, Velikova G, Price G, Draper H, Blazeby J, Scott J, Coast J, Norquist J, Brown J, Haywood K, Johnson LL, Campbell L, Frank L, von Hildebrand M, Brundage M, Palmer M, Kluetz P, Stephens R, Golub RM, Mitchell S, Groves T (2018) Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA 319:483\u2013494","journal-title":"JAMA"},{"key":"719_CR2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","volume":"309","author":"M Calvert","year":"2013","unstructured":"Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, CONSORT PRO Group (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309:814\u2013822","journal-title":"JAMA"},{"key":"719_CR3","unstructured":"EORTC Quality of Life Group (2016) Manual for the use of EORTC measures in daily clinical practice. Brussels"},{"key":"719_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","volume":"14","author":"TW LeBlanc","year":"2017","unstructured":"LeBlanc TW, Abernethy AP (2017) Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. Nat Rev Clin Oncol 14:763\u2013772","journal-title":"Nat Rev Clin Oncol"},{"key":"719_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11136-019-02320-8","volume":"29","author":"E Austin","year":"2020","unstructured":"Austin E, LeRouge C, Hartzler AL, Segal C, Lavallee DC (2020) Capturing the patient voice: implementing patient-reported outcomes across the health system. Qual Life Res 29:347\u2013355","journal-title":"Qual Life Res"},{"key":"719_CR6","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/annonc\/mdv181","volume":"26","author":"D Howell","year":"2015","unstructured":"Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, Liberty J (2015) Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol 26:1846\u20131858. https:\/\/doi.org\/10.1093\/annonc\/mdv181","journal-title":"Ann Oncol"},{"key":"719_CR7","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1200\/JCO.2005.05.2951","volume":"24","author":"JM Blazeby","year":"2006","unstructured":"Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J (2006) Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 24:3178\u20133186","journal-title":"J Clin Oncol"},{"key":"719_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1470-2045(16)30125-5","volume":"17","author":"D Cella","year":"2016","unstructured":"Cella D, Gr\u00fcnwald V, Nathan P, Doan J, Dastani H, Taylor F, Bennett B, DeRosa M, Berry S, Broglio K, Berghorn E, Motzer RJ (2016) Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 17:994\u20131003","journal-title":"Lancet Oncol"},{"key":"719_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"719_CR10","doi-asserted-by":"crossref","unstructured":"Giesinger JM, Efficace F, Aaronson NK, Calvert M, Kyte D, Cottone F, et al (2021) Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review. Value Health 24(8)","DOI":"10.1016\/j.jval.2020.11.004"},{"key":"719_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s11136-013-0534-2","volume":"23","author":"AB Smith","year":"2014","unstructured":"Smith AB, Cocks K, Parry D, Taylor M (2014) Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G). Qual Life Res 23:971\u2013976","journal-title":"Qual Life Res"},{"key":"719_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejca.2018.09.005","volume":"104","author":"JZ Musoro","year":"2018","unstructured":"Musoro JZ, Bottomley A, Coens C, Eggermont AM, King MT, Cocks K, et al (2018) Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma. Eur J Cancer 104:169\u2013181. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.005","journal-title":"Eur J Cancer"},{"key":"719_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ygyno.2020.09.007","volume":"159","author":"JZ Musoro","year":"2020","unstructured":"Musoro JZ, Coens C, Greimel E, King MT, Sprangers MAG, Nordin A, van Dorst EBL, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A, EORTC Gynecological and Quality of Life Groups (2020) Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer. Gynecol Oncol 159:515\u2013521","journal-title":"Gynecol Oncol"},{"key":"719_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","volume":"118","author":"JM Giesinger","year":"2020","unstructured":"Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, et al (2020) Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1\u20138. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.10.003","journal-title":"J Clin Epidemiol"},{"key":"719_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/jpm.2020.0159","volume":"24","author":"MJ Pilz","year":"2021","unstructured":"Pilz MJ, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, Holzner B, van Leeuwen M, Loth FLC, Petersen MA, Ramage J, Tomaszewski KA, Young T, Giesinger JM (2021) Evaluating the thresholds for clinical importance of the EORTC QLQ-C15-PAL in patients receiving palliative treatment. J Palliat Med 24:397\u2013404","journal-title":"J Palliat Med"},{"key":"719_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","volume":"107","author":"S Nolte","year":"2019","unstructured":"Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, et al (2019) General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer 107:153\u2013163. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.024","journal-title":"Eur J Cancer"},{"key":"719_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2020.06.002","volume":"137","author":"S Nolte","year":"2020","unstructured":"Nolte S, Waldmann A, Liegl G, Petersen MA, Groenvold M, Rose M (2020) Updated EORTC QLQ-C30 general population norm data for Germany. Eur J Cancer 137:161\u2013170. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.002","journal-title":"Eur J Cancer"},{"key":"719_CR18","doi-asserted-by":"crossref","unstructured":"Lehmann J, Giesinger JM, Nolte S, Sztankay M, Wintner LM, Liegl G, et al (2020) Normative data for the EORTC QLQ-C30 from the Austrian general population. Health Qual Life Outcomes 18(1):275","DOI":"10.1186\/s12955-020-01524-8"},{"key":"719_CR19","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1186\/s12889-022-13211-y","volume":"22","author":"MJ Pilz","year":"2022","unstructured":"Pilz MJ, Gamper EM, Efficace F, Arraras JI, Nolte S, Liegl G, Rose M, Giesinger JM, EORTC Quality of Life Group (2022) EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals. BMC Public Health 22:1040","journal-title":"BMC Public Health"},{"key":"719_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12955-021-01820-x","volume":"19","author":"JI Arraras","year":"2021","unstructured":"Arraras JI, Nolte S, Liegl G, Rose M, Manterola A, Illarramendi JJ, Zarandona U, Rico M, Teiejria L, Asin G, Hernandez I, Barrado M, Vera R, Efficace F, Giesinger JM, EORTC Quality of Life Group (2021) General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition. Health Qual Life Outcomes 19:208","journal-title":"Health Qual Life Outcomes"},{"key":"719_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1515\/raon-2017-0021","volume":"51","author":"V Velenik","year":"2017","unstructured":"Velenik V, Secerov-Ermenc A, But-Hadzic J, Zadnik V (2017) Health-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general slovenian population. Radiol Oncol 51:342\u2013350. https:\/\/doi.org\/10.1515\/raon-2017-0021","journal-title":"Radiol Oncol"},{"key":"719_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/028418600750013384","volume":"39","author":"H Michelson","year":"2000","unstructured":"Michelson H, Bolund C, Nilsson B, Brandberg Y (2000) Health-related quality of life measured by the EORTC QLQ-C30\u2013reference values from a large sample of Swedish population. Acta Oncol 39:477\u2013484. https:\/\/doi.org\/10.1080\/028418600750013384","journal-title":"Acta Oncol"},{"key":"719_CR23","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s11136-014-0675-y","volume":"23","author":"T Juul","year":"2014","unstructured":"Juul T, Petersen MA, Holzner B, Laurberg S, Christensen P, Gr\u00f8nvold M (2014) Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity. Qual Life Res 23:2183\u20132193. https:\/\/doi.org\/10.1007\/s11136-014-0675-y","journal-title":"Qual Life Res"},{"key":"719_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ejca.2010.11.004","volume":"47","author":"LV van de Poll-franse","year":"2011","unstructured":"van de Poll-franse LV, Mols F, Gundy CM, Creutzberg CL, Nout RA, Verdonck-de Leeuw IM, et al (2011) Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer 47:667\u2013675. https:\/\/doi.org\/10.1016\/j.ejca.2010.11.004","journal-title":"Eur J Cancer"},{"key":"719_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2478\/raon-2019-0047","volume":"53","author":"SL Ficko","year":"2019","unstructured":"Ficko SL, Pejsa V, Zadnik V (2019) Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires. Radiol Oncol 53:337\u2013347. https:\/\/doi.org\/10.2478\/raon-2019-0047","journal-title":"Radiol Oncol"},{"key":"719_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2019.10.031","volume":"125","author":"J Mierzynska","year":"2020","unstructured":"Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, et al (2020) Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer 125:69\u201382. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.031","journal-title":"Eur J Cancer"},{"key":"719_CR27","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jclinepi.2006.12.014","volume":"60","author":"YH Yun","year":"2007","unstructured":"Yun YH, Kim SH, Lee KM, Park SM, Kim YM (2007) Age, sex, and comorbidities were considered in comparing reference data for health-related quality of life in the general and cancer populations. J Clin Epidemiol 60:1164\u20131175. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.12.014","journal-title":"J Clin Epidemiol"},{"key":"719_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5694\/mja2.50207","volume":"210","author":"R Mercieca-Bebber","year":"2019","unstructured":"Mercieca-Bebber R, Costa DS, Norman R, Janda M, Smith DP, Grimison P, et al (2019) The EORTC quality of life questionnaire for cancer patients (QLQ-C30): Australian general population reference values. Med J Aust 210:499\u2013506. https:\/\/doi.org\/10.5694\/mja2.50207","journal-title":"Med J Aust"},{"key":"719_CR29","first-page":"110","volume":"29","author":"T Morishima","year":"2019","unstructured":"Morishima T, Matsumoto Y, Koeda N, Shimada H, Maruhama T, Matsuki D, Nakata K, Ito Y, Tabuchi T, Miyashiro I (2019) Impact of comorbidities on survival in gastric, colorectal, and lung cancer patients. J Clin Epidemiol 29:110\u2013115","journal-title":"J Clin Epidemiol"},{"key":"719_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3122\/jabfm.2007.05.060225","volume":"20","author":"JJ Mao","year":"2007","unstructured":"Mao JJ, Armstrong K, Bowman MA, Xie SX, Kadakia R, Farrar JT (2007) Symptom burden among cancer survivors: impact of age and comorbidity. J Am Board Fam Med 20:434\u2013443","journal-title":"J Am Board Fam Med"},{"key":"719_CR31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10549-014-2917-7","volume":"145","author":"M Kiderlen","year":"2014","unstructured":"Kiderlen M, de Glas NA, Bastiaannet E, van de Water W, de Craen AJ, Guicherit OR, Merkus JW, Extermann M, van de Velde CJ, Liefers GJ (2014) Impact of comorbidity on outcome of older breast cancer patients: a FOCUS cohort study. Breast Cancer Res Treat 145:185\u2013192","journal-title":"Breast Cancer Res Treat"},{"key":"719_CR32","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, Grove L, EL Jr S (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441\u20132447","journal-title":"JAMA"},{"key":"719_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11764-020-00876-w","volume":"14","author":"A Pate","year":"2020","unstructured":"Pate A, Lowery J, Kilbourn K, Blatchford PJ, McNulty M, Risendal B (2020) Quality of life and the negative impact of comorbidities in long-term colorectal cancer survivors: a population-based comparison. J Cancer Surviv 14:653\u2013659","journal-title":"J Cancer Surviv"},{"key":"719_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3322\/caac.21342","volume":"66","author":"D Sarfati","year":"2016","unstructured":"Sarfati D, Koczwara B, Jackson C (2016) The impact of comorbidity on cancer and its treatment. CA Cancer J Clin 66:337\u2013350","journal-title":"CA Cancer J Clin"},{"key":"719_CR35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/0284186X.2017.1324213","volume":"56","author":"J Nilsson","year":"2017","unstructured":"Nilsson J, Berglund A, Bergstr\u00f6m S, Bergqvist M, Lambe M (2017) The role of comorbidity in the management and prognosis in non-small cell lung cancer: a population-based study. Acta Oncol 56:949\u2013956","journal-title":"Acta Oncol"},{"key":"719_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14737167.2016.1239533","volume":"16","author":"SH Rim","year":"2016","unstructured":"Rim SH, Gp Jr G, Yabroff KR, McGraw KA, Ekwueme DU (2016) The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review. Expert Rev Pharmacoecon Outcomes Res 16:579\u2013589","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"719_CR37","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Eheman CR, Ward EM (2014) Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120:1290\u20131314","journal-title":"Cancer"},{"key":"719_CR38","doi-asserted-by":"publisher","first-page":"e1429","DOI":"10.1002\/cnr2.1429","volume":"5","author":"H Ludwig","year":"2022","unstructured":"Ludwig H, Bailey AL, Marongiu A, Khela K, Milligan G, Carlson KB, et al (2022) Patient-reported pain severity and health-related quality of life in patients with multiple myeloma in real world clinical practice. Cancer Rep (Hoboken) 5:e1429. https:\/\/doi.org\/10.1002\/cnr2.1429","journal-title":"Cancer Rep (Hoboken)"},{"key":"719_CR39","doi-asserted-by":"publisher","first-page":"112946","DOI":"10.1016\/j.ejca.2023.112946","volume":"190","author":"JC Reijneveld","year":"2023","unstructured":"Reijneveld JC, Machingura A, Coens C, Taphoorn MJB, Taal W, Clement PM, et al (2023) Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p\/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091). Eur J Cancer 190:112946. https:\/\/doi.org\/10.1016\/j.ejca.2023.112946","journal-title":"Eur J Cancer"},{"key":"719_CR40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A (2002) Quality of life research within the EORTC\u2014 the EORTC QLQ-C30. Eur J Cancer 38:125\u2013133","journal-title":"Eur J Cancer"},{"key":"719_CR41","volume-title":"The EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for research and treatment of cancer, Brussels","edition":"3rd edn"},{"key":"719_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","volume":"69","author":"JM Giesinger","year":"2016","unstructured":"Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, et al (2016) Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol 69:79\u201388. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.08.007","journal-title":"J Clin Epidemiol"},{"key":"719_CR43","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jval.2019.06.004","volume":"22","author":"F Efficace","year":"2019","unstructured":"Efficace F, Cottone F, Sommer K, Kieffer J, et al (2019) Validation of the European Organisation for Research and treatment of cancer quality of life questionnaire core 30 summary score in patients with hematologic malignancies. Value Health 22:1303\u20131310","journal-title":"Value Health"},{"key":"719_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.04.016","volume":"100","author":"MA Petersen","year":"2018","unstructured":"Petersen MA, Aaronson NK, Arraras JI, Chie WC, Conroy T, Costantini A, Dirven L, Fayers P, Gamper EM, Giesinger JM, Habets EJJ, Hammerlid E, Helbostad J, Hjermstad MJ, Holzner B, Johnson C, Kemmler G, King MT, Kaasa S, Loge JH, Reijneveld JC, Singer S, Taphoorn MJB, Thamsborg LH, Tomaszewski KA, Velikova G, Verdonck-de Leeuw IM, Young T, Groenvold M, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (2018) The EORTC CAT Core-the computer adaptive version of the EORTC QLQ-C30 questionnaire. Eur J Cancer 100:8\u201316","journal-title":"Eur J Cancer"},{"key":"719_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2018.11.023","volume":"107","author":"G Liegl","year":"2019","unstructured":"Liegl G, Petersen MA, Groenvold M, Aaronson NK, Costantini A, Fayers PM, Holzner B, Johnson CD, Kemmler G, Tomaszewski KA, Waldmann A, Young TE, Rose M, Nolte S, EORTC Quality of Life Group (2019) Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core. Eur J Cancer 107:133\u2013141","journal-title":"Eur J Cancer"},{"key":"719_CR46","unstructured":"United Nations Department of Economic and Social Affairs Population Division World population prospects: the 2017 revision"},{"key":"719_CR47","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/pon.4787","volume":"27","author":"S Subramaniam","year":"2018","unstructured":"Subramaniam S, Kong YC, Chinna K, Kimman M, Ho YZ, Saat N, Malik RA, Taib NA, Abdullah MM, Lim GC, Tamin NI, Woo YL, Chang KM, Goh PP, Yip CH, Bhoo-Pathy N (2018) Health-related quality of life and psychological distress among cancer survivors in a middle-income country. Psychooncology 27:2172\u20132179","journal-title":"Psychooncology"},{"key":"719_CR48","doi-asserted-by":"crossref","unstructured":"Schmidt H, Nordhausen T, Boese S, Vordermark D, Wheelwright S, Wienke A, Johnson CD (2018) Factors influencing global health related quality of life in elderly cancer patients: results of a secondary data analysis. Geriatrics 3(1):5","DOI":"10.3390\/geriatrics3010005"},{"key":"719_CR49","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s11764-018-0708-6","volume":"12","author":"H G\u00f6tze","year":"2018","unstructured":"G\u00f6tze H, Taubenheim S, Dietz A, Lordick F, Mehnert A (2018) Comorbid conditions and health-related quality of life in long-term cancer survivors-associations with demographic and medical characteristics. J Cancer Surviv 12:712\u2013720","journal-title":"J Cancer Surviv"},{"key":"719_CR50","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/pon.4845","volume":"27","author":"A Cummings","year":"2018","unstructured":"Cummings A, Grimmett C, Calman L, Patel M, Permyakova NV, Winter J, Corner J, Din A, Fenlon D, Richardson A, Smith PW, Members of CREW Study Advisory Committee, Foster C (2018) Comorbidities are associated with poorer quality of life and functioning and worse symptoms in the 5 years following colorectal cancer surgery: results from the ColoREctal Well-being (CREW) cohort study. Psychooncology 27:2427\u20132434","journal-title":"Psychooncology"},{"key":"719_CR51","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00277-015-2541-6","volume":"95","author":"F Efficace","year":"2016","unstructured":"Efficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F, et al (2016) The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Ann Hematol 95:211\u2013219","journal-title":"Ann Hematol"},{"key":"719_CR52","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.33348","volume":"127","author":"J Park","year":"2021","unstructured":"Park J, Rodriguez JL, O\u2019Brien KM, Nichols HB, Hodgson ME, Weinberg CR, Sandler DP (2021) Health-related quality of life outcomes among breast cancer survivors. Cancer 127:1114\u20131125","journal-title":"Cancer"},{"key":"719_CR53","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","volume":"22","author":"A Bottomley","year":"2021","unstructured":"Bottomley A, Coens C, Mierzynska J, Blank CU, Mandal\u00e0 M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM, EORTC Melanoma Group (2021) Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 22:655\u2013664","journal-title":"Lancet Oncol"},{"key":"719_CR54","doi-asserted-by":"publisher","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","volume":"7","author":"M Roussel","year":"2020","unstructured":"Roussel M, Moreau P, Hebraud B, Laribi K, Jaccard A, Dib M, Slama B, Dorvaux V, Royer B, Frenzel L, Zweegman S, Klein SK, Broijl A, Jie KS, Wang J, Vanquickelberghe V, de Boer C, Kampfenkel T, Gries KS, Fastenau J, Sonneveld P (2020) Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol 7:e874\u2013e883","journal-title":"Lancet Haematol"},{"key":"719_CR55","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.ijrobp.2020.10.030","volume":"109","author":"CCB Post","year":"2021","unstructured":"Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger NPB, Ledermann JA, Khaw P, D\u2019Amico R, Fyles A, Baron MH, Kitchener HC, Nijman HW, Lutgens LCHW, Brooks S, J\u00fcrgenliemk-Schulz IM, Feeney A, Goss G, Fossati R, Ghatage P, Leary A, Do V, Lissoni AA, McCormack M, Nout RA, Verhoeven-Adema KW, Vthbm S, Putter H, Creutzberg CL (2021) Long-term toxicity and health-related quality of life after adjuvant chemoradiation therapy or radiation therapy alone for high-risk endometrial cancer in the randomized PORTEC-3 trial. Int J Radiat Oncol Biol Phys 109:975\u2013986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"719_CR56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2021.07.019","volume":"156","author":"S Oertelt-Prigione","year":"2021","unstructured":"Oertelt-Prigione S, de Rooij BH, Mols F, Oerlemans S, Husson O, Schoormans D, Haanen JB, van de Poll-franse LV (2021) Sex-differences in symptoms and functioning in >5000 cancer survivors: results from the PROFILES registry. Eur J Cancer 156:24\u201334","journal-title":"Eur J Cancer"},{"key":"719_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/agm2.12051","volume":"2","author":"S Shrestha","year":"2019","unstructured":"Shrestha S, Shrestha S, Khanal S (2019) Polypharmacy in elderly cancer patients: challenges and the way clinical pharmacists can contribute in resource-limited settings. Aging Med 2:42\u201349","journal-title":"Aging Med"},{"key":"719_CR58","doi-asserted-by":"crossref","unstructured":"Koczwara B (ed) (2016) Cancer and chronic conditions: how do we measure comorbidity? Springer","DOI":"10.1007\/978-981-10-1844-2"},{"key":"719_CR59","doi-asserted-by":"crossref","unstructured":"Freisling H, Viallon V, Lennon H, Bagnardi V, Ricci C, Butterworth AS, Sweeting M, Muller D, Romieu I, Bazelle P, Kvaskoff M, Arveux P, Severi G, Bamia C, K\u00fchn T, Kaaks R, Bergmann M, Boeing H, Tj\u00f8nneland A, Olsen A, Overvad K, Dahm CC, Men\u00e9ndez V, Agudo A, S\u00e1nchez MJ, Amiano P, Santiuste C, Gurrea AB, Tong TYN, Schmidt JA, Tzoulaki I, Tsilidis KK, Ward H, Palli D, Agnoli C, Tumino R, Ricceri F, Panico S, Picavet HSJ, Bakker M, Monninkhof E, Nilsson P, Manjer J, Rolandsson O, Thysell E, Weiderpass E, Jenab M, Riboli E, Vineis P, Danesh J, Wareham NJ, Gunter MJ, Ferrari P (2020) Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study. BMC Med 18","DOI":"10.1186\/s12916-019-1474-7"},{"key":"719_CR60","unstructured":"OECD - Social Policy Division - Directorate of Employment, Labour and Social Affairs (2019) OECD family database: CO3.1: educational attainment by gender. https:\/\/www.oecd.org\/els\/family\/CO3_1_Educational_attainment_by_gender.pdf. Accessed 6 Feb 2023"},{"key":"719_CR61","unstructured":"International Diabetes Federation (2021) Diabetes Atlas: diabetes prevalence (% of population ages 20 to 79) \u2013 France. https:\/\/data.worldbank.org\/indicator\/SH.STA.DIAB.ZS?locations=FR. Accessed 2 May 2023"},{"key":"719_CR62","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.lpm.2018.12.004","volume":"48","author":"G Fond","year":"2019","unstructured":"Fond G, Lancon C, Auquier P, Boyer L (2019) Pr\u00e9valence de la d\u00e9pression majeure en France en population g\u00e9n\u00e9rale et en populations sp\u00e9cifiques de 2000 \u00e0 2018: une revue syst\u00e9matique de la litt\u00e9rature [Prevalence of major depression in France in the general population and in specific populations from 2000 to 2018: a systematic review of the literature]. Presse Med 48:365\u2013375","journal-title":"Presse Med"},{"key":"719_CR63","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1997","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J (1997) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245\u20131251","journal-title":"J Clin Epidemiol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00719-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:10:34Z","timestamp":1723126234000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["719"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00719-7","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was sought as the study is based on panel data. According to the NHS Health Research Authority and the European Pharmaceutical Market Research Association (EphMRA), panel research does not require ethical approval if ethical guidelines are followed. The survey was distributed via the GfK SE (member of EphMRA) and obtained informed consent by each participant before the study. All data were collected anonymously and identifcation of the respondents through the authors is impossible. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report there are no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}